SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-260990
Filing Date
2023-10-24
Accepted
2023-10-23 19:45:31
Documents
16
Period of Report
2023-10-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d583174d8k.htm   iXBRL 8-K 40344
2 EX-4.1 d583174dex41.htm EX-4.1 78770
3 EX-4.2 d583174dex42.htm EX-4.2 79803
4 EX-10.1 d583174dex101.htm EX-10.1 207479
5 EX-10.2 d583174dex102.htm EX-10.2 119961
  Complete submission text file 0001193125-23-260990.txt   787568

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA harp-20231022.xsd EX-101.SCH 2857
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE harp-20231022_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE harp-20231022_pre.xml EX-101.PRE 11712
10 EXTRACTED XBRL INSTANCE DOCUMENT d583174d8k_htm.xml XML 3486
Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Filer) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38800 | Film No.: 231340849
SIC: 2836 Biological Products, (No Diagnostic Substances)